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Abstract 
Introduction: Chemotherapy is an important treatment in cancer (CA) care and is associated with numerous side 
effects. Early studies reported that patients cited nausea and vomiting as the most distressing symptoms when 
receiving chemotherapy. Despite continuing improvements in antiemetic therapies, nausea and vomiting 
following chemotherapy treatment for CA remains a significant clinical problem for many patients and there is 
correlation between the intensity of anticipatory nausea in the clinic prior to their treatment infusion and 
subsequent post treatment of nausea and vomiting.  
Since pharmacological treatments have failed to completely manage nausea and vomiting, exploring the 
complementary, non-pharmacological, approaches that can be used in addition to pharmacological approaches 
becomes paramount. Acupressure at the P6 point is a value-added technique in addition to pharmaceutics; 
management for women undergoing treatment for breast cancer to reduce the incidence and intensity of delayed 
chemotherapy induced nausea and vomiting (CINV), since up to 60% of patients had been reported nausea 
despite the use of antiemetics Aims: The first aim  is to examine the efficacy of P6-acupressure in preventing 
chemotherapy induced nausea and emesis associated with highly emetogenic chemotherapy (i.e. doxorubicin as 
adjuncts to standard 5-HT3 antiemetics (granisetron) and dexamethasone antiemetic given as part of routine care 
in reducing acute nausea (during the day of treatment) and delayed nausea (2-5 days) following the day of 
chemotherapy. The second aim is to examine the efficacy of the acupressure bands in reducing vomiting and in 
maintaining Quality of Life (QOL). Patients and methods: A randomised, double-blind, placebo controlled trial. 
One group received acupressure with bilateral stimulation of P6 (n=42), a second group received bilateral 
placebo stimulation, (n=42) and a third group received no acupressure wrist band and served as a control group, 
(n=42). Acupressure was applied using a Sea-Band (Sea- Band UK Ltd., Leicestershire, England) which had to 
wear for the 5 days following the chemotherapy administration. Assessments of acute and delayed nausea and 
emesis, OOL, patients' satisfaction, recommendation of treatment and requirement of rescue antiemetic were 
obtained. Results: No significant differences were found in the incidence of acute nausea or emesis 24- h 
following chemotherapy by treatment groups. Significant difference was found in the severity of early nausea (0-
6 scale) in the acupressure group M (SD) 1.62 (2.04) as compared to placebo group 2.17 (2.09), p=, 0006. 
The acupressure group had a statistically significant reduction in the incidence of delayed nausea 40% 
(17/42) as compared to the control group 62% (26/42) (p= ,0495). Further analyses indicated that significant 
difference existed in the intensity of delayed nausea by acupressure group mean (SD) 1.45 (1.73), p=, 0002 as 
compared to control 2.03 (1.91). Significant difference also existed in the intensity of delayed nausea by placebo 
group 1.33 (1.66), p=, 0010 as compared to control 2.03 (1.91). Here we noted a placebo effect. 
The percentage of the patients who had delayed moderate to very severe nausea day 2-5 (≥3 on 0-6 
scale) in the acupressure group is 55% (23/42 (p= 0206), in the placebo group 52% (22/42) (p= 0116), a 
statistically significant reduction existed as compared to control 79% (33/42). Here we noted a placebo effect. 
The incidence of delayed vomiting episodes day 2-5 was 48% (20/42), 64% (27/42), and 57% (24/42) 
in the acupressure, placebo and control group respectively. No significant differences were found between the 
groups.  
The mean of number of delayed emetic episodes day 2-5 was significantly less in the acupressure group 
2.7 (1.87) as compared to placebo 3.3 (1.91), p=,0022 and control groups 2.07(1.20), P= ,0005. Requirement of 
rescue antiemetic was significantly lower in P6-acupressure (55%, 23/42), as compared to control group (76%, 
32/42) (p= 0389). 
81% (35/42)) of the patients in acupressure group were significantly satisfied with P6-acupressure as 
compared to placebo group 64% (27/42), p= 0.0471. 79% (34/42)) of the patients in acupressure group would 
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recommend P6-acupressure to another patients as compared to placebo group 62% (26/42), p= 0,0533 . 
No statistically significant differences between groups were observed for the overall items response rate 
of the FACT-Scale which were 74/108, 67/108, 69/108 in the acupressure, placebo and control group 
respectively. Conclusion: P-6 Acupressure is efficacious for control of delayed chemotherapy related nausea and 
emesis and is a value-added method in addition to pharmaceutical management for women undergoing treatment 
for breast cancer. Placebo effect of acupressure decreased severity of delayed nausea day 2-5 but the mean of 
number of delayed emetic episodes and need of rescue antiemetics were reduced only by acupressure with the 
correct P6 point stimulation.   
Keywords: breast cancer, chemotherapy, nausea, vomiting, acupressure. 
 
1. Introduction 
Cancer (Ca) is a group of diseases characterized by uncontrolled and growth spread of abnormal cells. It may be 
caused by internal factors (inherited mutation, hormonal, immune, conditions and mutation from metabolism) or 
external ones (tobacco, radiation, chemicals and infectious organisms). Cancer is prevalent all over the world 
among developed and developing nations; it affects both sexes at all ages. Breast cancer is the first leading cause 
of death of female cancers. Over 175,000 women in the US are diagnosed with breast cancer each year, the 
prevalence rising up to 7% over age 70 in the near future (LouWman et al, 2007 ). It occupies the first of 
female's CA among the Palestinians with incidence (15.1%) per 100,000 population, and mortality rate (5.2 %) 
per 100,000 females (MOH report 2005). CA treatment is based on chemotherapy, radiotherapy and surgical 
interventions. Radiotherapy is not available in the Palestinian territories, but the other two types are accessible at 
most governmental health settings at Gaza Strip and West Bank (WB) (MOH report 2005).  
Chemotherapy is an important treatment in cancer care and is associated with numerous side effects 
such as bone marrow suppression, increased susceptibility to infection, nephrotoxicity, anorexia, alopecia, 
diarrhea, nausea and vomiting (Vincent et al, 2001). Early studies reported that patients cited nausea and 
vomiting as the most distressing symptoms when receiving chemotherapy (Coates et al 1983, Deboer- Dennert et 
al 1997). Beyond their distressing effects, severe nausea and vomiting can lead to nutritional deficiencies, 
dehydration and electrolyte imbalance and fatigue (Hawthorn 1995, Joss et al 1990, king 1997). Despite 
continuing improvements in antiemetic therapies, nausea and vomiting following chemotherapy treatment for 
CA remains a significant clinical problem for many patients and there is correlation between the intensity of 
anticipatory nausea in the clinic prior to their treatment infusion and subsequent post treatment nausea during the 
24 h after the infusion (Bovbjer 2006).   
Historically, antiemetic treatment has been improved first by the introduction in 1981 of high-dose 
metoclopramide which reduced the amount of emesis (Gralla et al 1981), second by the development of 
serotonin (5-HT3) antagonist in the early 1990s, potentiated by concomitant use of corticosteroids which further 
improved control of emesis (Grunberg, & Kesketh 1993). Despite these improvements, nausea and vomiting 
remain a problem for patients (Grunberg et al 2004). Recently a new drug, the neurokinin NK (1) receptor 
antagonist has been shown to have a better effect on preventing both acute and delayed CINV for patients treated 
with highly emetogenic chemotherapy (Dando & Perry 2004, Dewit et al 2004). Non-pharmacological 
interventions such as music (Ezzone et al 1998), acupressure (Dibbel et al 2000) and progressive muscle 
relaxation (Molassiotis et al 2002) have also been shown to reduce CINV. 
The 5-HT3 antagonists, are more effective than prior medications in preventing chemotherapy induced 
vomiting (DeMulder 1990, Marty 1990, Roscoe et al 2000, Osoba et al 1997). However, chemotherapy related 
nausea is not as well controlled by these drugs and remains a significant problem (Roscoe et al 2000). 
Uncontrolled nausea and vomiting (NV) can interfere with adherence to treatment regimens, and may cause 
oncologists to reduce chemotherapy doses (Morrow and Dobkin 1988, Stewart 1990).  Nausea and vomiting can 
also disrupt the activities of daily living, because lost time from work, increase anxiety and depression, (king 
1997) 
In one study involving 1,413 cancer patients undergoing chemotherapy, 80% experienced nausea to 
some degree, with 40% having at least one episode of vomiting (Roscoe et al 2000). Similarly, in a study, 76% 
of 322 patients who received chemotherapy regimens containing cisplatin, carboplatin, or doxorubicin 
experienced nausea following their first treatment, despite what was felt by physicians to be adequate antiemetic 
prophylaxis. Of these 322 patients, 147(46%) had nausea of moderate severity or greater (Hickok et al 2003). 
Identifying methods to successfully prevent and alleviate treatment-related nausea remains a major clinical 
challenge.  
Since pharmacological treatments have failed to completely manage nausea and vomiting, exploring the 
complementary role of other, non-pharmacological, approaches that can be used in addition to pharmacological 
approaches becomes paramount. Acupressure at the P6 point is a value-added technique in addition to 
pharmaceutics; management for women undergoing treatment for breast cancer to reduce the amount and 
intensity of delayed CINV, since up to 60% of patients had been reported nausea despite the use of antiemetics 
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(Dibble et al 2007). 
Stimulation of the P6 acupuncture point located on the inside of the wrist with needles (acupuncture) or 
pressure (acupressure) has been used to relieve NV in traditional Chinese medicine for centuries (Beinfield and 
Korngold 1995). Literature reviews indicate that acupuncture and acupressure may provide relief from these 
symptoms (Kaptchuk  2002, Mayer  2000, Vickers 1996). Specifically, needling or applying pressure (generally 
with an acupressure band such as the SeaBand®, (Sea Band UK Ltd., Leicestershire, England) to an acupoint 
have been efficacious in alleviating morning sickness (Belluomini et al 1994, Carlsson et al 2000, DeAloysio 
and Penacchioni 1992, Norheim et al 2001, Evans et al 1993, Slotnick  2001), motion sickness (Hu 1992, 1995, 
Bertolucci and DiDario 1995,  Stern et al 2001, Alkaissi 2005), post-surgical nausea (Fan et al 1997, Ferrara-
Love et al 1996, Gieron  et al 1993, Harmon et al  2000, Ho et al 1996, Stein  et al 1997, Alkaissi 1999, 2002, 
Zarate  et al 2001) and NV associated with chemotherapy (Dundee  1989,1991,  Roscoe 2002, 2003, Shen et al 
2000, Dibble  2000, Williams et al1992, Treish et al  2002, Bushunow et al 2002, Dundee and  Yang  1990, 
Stannard  1989, Pearl et al1999, Noga et al 2002).  
Beginning in the early 1990s, studies assessing the efficacy of electrical stimulation (acustimulation) 
using portable Transcutaneous Electrical Nerve Stimulator (TENS) wrist bands to the P6 acupuncture point for 
control of nausea have also been conducted. All of these studies used the Relief Band (Woodside Biomedical, 
Carlsbad, CA), which is marketed for this purpose and has United States Food and Drug Administration (FDA) 
clearance as treatment for NV.  In 1998, the National Institutes of Health Consensus Statement on Acupuncture 
concluded that promising results have emerged showing the efficacy of acupuncture in adult postoperative and 
chemotherapy induced nausea and vomiting. The acupuncture point, P6 had been the point used in most of the 
trials (Ezzo et al 2006).  
Acupressure seems to be a good way to complement anti emetic pharmacotherapy, as it is safe, 
convenient and with minimal costs involved. These make it a cost-effective intervention. It is not known why 
acupressure works, and partly these results may be attributed to a placebo effect, as also highlighted in the study 
by (Roscoe et al 2003, Burish  et al 1992 ) declared that  psychological reasons may also partly explain these 
results. Indeed, it was previously reported that relaxation and distraction techniques have significantly improved 
nausea and vomiting in breast cancer patients receiving chemotherapy (Molassiotis 2002). Acupressure is easily 
learnt and taught and patients should be informed about its potential role and taught how to apply it. Self-
administered acupressure appears to have a protective effect for acute nausea (Ezzo 2007). 
There have been recent advances in chemotherapy-induced nausea and vomiting using 5-HT3 inhibitors 
and dexamethasone. However, many still experience these symptoms, and expert panels encourage additional 
methods to reduce these symptoms (Ezzo et al 2007). Research supports the effectiveness of acupuncture and 
acupressure for the treatment of chemotherapy-induced nausea and vomiting. Used in conjunction with current 
antiemetic drugs, acupuncture and acupressure have been shown to be safe and effective for relief of the nausea 
and vomiting resulting from chemotherapy (Collins and Thomas, 2004).  
Studies have confirmed that the key to successful management of CINV is to prevent symptoms before 
they occur (Goodman 1997, Morrow et al 1998). Assessment evaluation of a cancer patient's general condition 
and a determination of how he or she feels is the first step in managing symptoms (Dodd et al 2001). Different 
approaches to symptom assessment may be adopted, from unstructured communication between patients and 
healthcare professionals to the use of documentation such as checklists or diaries. Research suggests that 
systematic assessment of symptoms is associated with reduced symptom distress over time (Sarna 1998). 
Chemotherapy-induced nausea and vomiting is classified as either "acute" within 24 h post 
chemotherapy or "delayed" nausea that occurs on Days 2–5 of the chemotherapy cycle is particularly 
troublesome because there is no reliable pharmacological treatment for this problem (Morrow et al 1996, 1998). 
The American Society of Clinical Oncology (ASCO) recommendations include giving potential 5-HT3 receptor 
antagonists plus corticosteroids before chemotherapy to patients receiving chemotherapy that are at high risk of 
emesis. Nevertheless, many patients still experience nausea and vomiting related to chemotherapy. Therefore, 
the expert panels emphasize the need for evaluation of additional ways to reduce these symptoms (Gralla et al 
1981, Hesketh et al 1998). The need for additional relief has led to interest in non-pharmacological adjuncts to 
drugs like acupuncture or acupressure. Combining antiemetics with other non-pharmacological treatments may 
prove more effective in decreasing nausea than antiemetics alone (Molassiotis et al 2006).  
Acupressure at the P6 point is a value-added technique in addition to pharmaceutical management for 
women undergoing treatment for breast cancer to reduce the amount and intensity of delayed CINV (Dibble et al 
2007). Implication for practice even with the best anti emetic pharmacological agents, 60% of cancer patients 
continue to experience nausea and vomiting when under going chemotherapy treatment (Collins et al 2004). 
Interestingly, several studies reviewed by Morrow and Roscoe (1997) have found that women, compared to men, 
are more susceptible to nausea caused by classical conditioning, as evidenced by the fact that women are more 
likely to experience nausea in anticipation of chemotherapy. 
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2. Statement of the Problem 
Complete control of chemotherapy-induced nausea and vomiting (NV) remains elusive despite decades of 
research on pharmacological antiemetics. Nausea in particular remains a significant problem with as many as 
75% of patients reporting the symptom at some point following their treatment. Approximately one-third of 
patients have nausea of  at least moderate intensity resulting in a significant reduction in quality of life (QOL). 
Delayed nausea that occurs on Days 2–5 of the chemotherapy cycle is particularly troublesome because there is 
no reliable pharmacological treatment for this problem. Not surprisingly, considerable effort and interest 
continue to be focused on developing better control of NV.  
Difficulty in completely managing chemotherapy-related nausea and vomiting may stem from the 
multiple pathways involved in the development of nausea and vomiting including the chemoreceptor trigger 
zone in the brain, dopamine receptors, personality, vestibular dysfunction, age, anxiety and psychological 
mechanisms. Despite advances in anti emetic research over the past decade and the introduction of  5-
hydroxytryptamine 3 (5-HT3) and Neurokinin1-receptor (NK1) antagonists, chemotherapy-related nausea and 
vomiting remain significant problems for the patients, decreasing their quality of life and negatively affecting 
their treatment experience, and  impacting physical, cognitive, social, emotional and role functioning.  
 
3.  The Importance of the Study 
Early studies reported that patients cited nausea and vomiting as the most distressing symptoms when receiving 
chemotherapy. Beyond their distressing effects, severe nausea and vomiting can lead to nutritional deficiencies, 
dehydration, electrolyte imbalance and fatigue. Despite continuing improvements in anti emetic therapies, 
nausea and vomiting following chemotherapy treatment for CA remains a significant clinical problem for many 
patients.  
Acupressure is a non-invasive, simple method that can be used with good results, no side effect or 
discomfort, and less cost in relieving NV among breast cancer patients receiving chemotherapy drugs. The 
measurement of patient perspective has become an important component of treatment evaluation in many areas 
of medicine. There is evidence that the patients´ view differs from their clinician's judgment. Thus there is a need 
to expand the outcome measures used. Using a questionnaire, which was deemed adequate by the patients, gave 
a high response rate and showed a wide range of symptoms associated with chemotherapy management.  
Despite continuing improvements in anti emetic therapies, nausea and vomiting following 
chemotherapy treatment for CA remains a significant clinical problem for many patients. Since pharmacological 
treatments have failed to completely manage nausea and vomiting, exploring the complementary role of other, 
non-pharmacological, approaches that can be used in addition to pharmacological approaches becomes 
paramount. Evidence is emerging that the stimulation of acupuncture points, particularly the Neiguan (P6) 
acupuncture point is helpful in controlling NV. While no theory that is generally accepted by the scientific 
community adequately explains how stimulation of the P6 acupuncture point reduces nausea, recent reviews 
have concluded that the practice does provide relief for a significant proportion of patients. 
 
4.  Hypothesis 
Breast cancer patients undergoing their second cycle of chemotherapy using acupressure wristbands in addition 
to anti emetics over 5 days will have significantly lower nausea, retching and vomiting compared to breast 
cancer patients receiving anti emetics only.  
 
5.  Materials and Methods 
The study was approved by the Ethics Committee at the Faculty of Higher Education at An-Najah National 
University and the Ministry of Health, Nablus Palestine. One hundred twenty six women, 18 years of age or 
older who are beginning their second cycle of chemotherapy for breast cancer treatment and nausea/vomiting 
with their previous cycle are randomized prior to chemotherapy to one of three groups after obtaining the verbal 
informed consent. 
Group 1, Acupressure to P6 point (active) (n=42). The P6 (Neiguan), a point located on the pericardial 
meridian, which is found three fingers’ breadth (approximately 5 cm) proximal to the proximal flexor palmar 
crease, about 1 cm deep between the tendons of flexor carpi radialis and palmaris longus is supposed to have an 
effect on post-operative nausea and vomiting (A barefoot doctor´s manual 1990). A Sea-Band (Sea- Band UK 
Ltd., Leicestershire, England) carries a plastic pearl which is fastened to apply pressure on P6. Both forearms are 
used. These points are marked with water-resistant ink so that the bands could be properly replaced if removed. 
The areas are draped with a dressing during the stay in the hospital. The nurses giving chemotherapy and the 
nurses on the ward, although aware that stimulation is being performed, are not aware of the location of P6. 
Group 2, Acupressure to none acupoint (placebo (n=42). A point on the dorsal side of both forearms, 
four fingers’ breadth proximal to the proximal flexor palmar crease was used for placebo stimulation. These 
points were marked in the same way as with the active acupressure. Sea-Band was used for stimulation, and the 
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same precautions were taken to keep the stimulation blinded (see above). 
Group 3, Usual care only (control) (n=42). These patients were informed in the same way as the 
acupressure and placebo groups. Instructions for care and assessment are the same, as are the registrations of 
nausea and vomiting at home. 
All subjects will complete a daily log for 5 days containing measures of nausea and vomiting and 
recording methods (including antiemetics) used to control these symptoms. 
 
5.1 Design 
This is a multicenter, prospective, consecutive, double blind and placebo-controlled clinical trial. 
 
5.2  Inclusion criteria  
(i) A breast cancer diagnosis, stage of cancer I–III, (ii) beginning their second cycle of chemotherapy for breast 
cancer treatment, (iii) had nausea/vomiting with their previous cycle, (iiii) willing to sign a consent form. 
 
5.3   Exclusion criteria 
(i) women received palliative chemotherapy, (ii) life expectancy is less than 3 months, (iii) had metastatic 
disease, (iiii) suffered from bowel obstruction, (v) undergoing concurrent radiotherapy or interferon treatment,  
 
5.4  Randomization 
After agreeing to participate in the study, the patients were randomised using the envelope method. Accordingly, 
a pack of sealed envelopes including a card with either the word ‘acupressure group’, “placebo group” or 
‘control group’ written on it, was given to a staff nurse unrelated to the study; the patient will pick one envelope 
after she agrees to take part in the study. Depending on which card was selected patients allocated to their 
respective group.  
 
5.5 Blindness 
The Sea-Bands wrapped with a dressing bandage during the trial period. Neither the observer nor the subjects 
know if P6 or placebo stimulation was given. 
 
5.6  Prophylactic antiemetic treatment 
All patients received standard antiemetics before chemotherapy with a 5-HT3 receptor antagonist (granisetron 
3mg) and dexamethasone 4mg. 
Group (1) received granisetron 3mg and dexamethasone 4mg, plus Acupressure to P6 point,  
Group (2) received granisetron 3mg and dexamethasone 4mg, plus Acupressure to none acupoint (placebo). 
Group 3 received granisetron 3mg and dexamethasone 4mg, and usual care only (a control event group). The 
drugs administered intravenously over 2—5 min immediately before induction of chemotherapy. 
 
5.7 Setting 
Patients are recruited from three oncology centres located throughout the West Bank (Al Watani Hospital in 
Nablus, Jeneen & Biet Jala Hospitals ). These Clinical Oncology centres are potentially eligible for the study. 
 
5.8 Intervention 
Acupressure wristbands (Sea-Band™, Sea-Band Ltd., Leicestershire, UK) were used (Fig. V). These bands are 
elastic wrist bands with a 1 cm protruding round plastic button (stud). Patients wear the wristbands with the stud 
pressing the P6 acupoint, which is located on the anterior surface of the forearm, approximately three-finger 
width up from the crease of the wrist between the tendons of the palmaris longus and flexor carpi radialis. Wrist 
bands are used bilaterally.  
 
5.9 Measures 
At the time of consent, patients provided demographic information about the patients’ age, marital status and 
education, details concerning prior experience with NV, for example, nausea during pregnancy, susceptibility to 
motion sickness, and so on, menstruation, and smoking. Clinical data included the chemotherapy regime and 
antiemetics used. The patients were asked to assess their degree of nausea during administration of 
chemotherapy in the hospital. Nausea and vomiting were measured by a patient report diary developed for this 
purpose by (Burish et al 1987, Carey and Burish 1988). Each day was divided into 4 segments (morning, 
afternoon, evening, and night) and patients reported the severity of nausea and number of vomiting episodes for 
each period on the day of treatment and on the four following days (20 total reporting times).  
Severity of nausea was assessed on a 7-point rating scale, anchored at one end by 0 = “Not at all 
nauseated” and at the other end by 6 = “Extremely nauseated.” The description “Moderately nauseated” was 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol.41, 2016 
 
10 
centred on the scale above the 3. Patients were given the questionnaires to complete at home over the five days 
immediately following treatment and returned them to the practice site. Anti emetics rescue medication was used 
and the number of vomiting episodes were recorded for the same time intervals as part of the diary. 
 
5.10 Quality of life instrument: FACT-G 
QOL was assessed using the Functional Assessment of Cancer Therapy Scale-General (FACT-G). The FACT-G 
is a 27-item scale (higher scores = better QOL) developed specifically for use in cancer clinical trials (Cella 
1993).  The FACT-G consists of  5 subscales; physical well being (PWB; 7 items), social/family well being 
(SWB; 7 items), emotional well being (EWB; 6 items), functional well being (FWB; 7 items).  It is used 
internationally and has undergone extensive psychometric testing: test/retest reliability coefficients range from 
0.82 to 0.92, internal consistency of subscales measures range from 0.60 to 0.89) (Ward 1997). The FACT-G is 
designed for self-assessment to be rated on a 5-point Likert scale. Patients can complete the FACT-G within 
about 10 min. Each of the inventory questions is scored from 0 (worst possible QOL) to 4 (best possible QOL) 
with some items being reversed. In addition to an overall quality of life score (the sum of all items), there are 
subscales for the areas of physical well-being, social well-being, emotional well-being and functional well-
being). Patients completed the measure four days after the day of chemotherapy and assessed QOL 
retrospectively since the treatment (Winstead-Fry and Schultz 1997). The sub-scores of the FACT-G were 
calculated according to the directions provided in the FACIT-Manual (all subscales are scored in such a way that 
higher values mean higher QOL  (Cella 1993). 
 
5.11 A feedback questionnaire 
It was completed by patients at the conclusion of the study period concerning use of diary book, Quality of life 
instrument: FACT-G. Satisfaction and recommendations for the band(s). Participants were given questionnaires 
to complete at home, with instructions to return them back in the pre-addressed envelopes that were provided. 
Reminder phone calls were made to patients, if necessary. The study concluded with the return of data following 
the next chemotherapy treatment. 
 
5.12 Assessment of patient satisfaction 
Patients estimated their satisfaction with their NV treatment using a Lickert-type scale 0-6, in which 0 = very 
much dissatisfied, and 6 = very much satisfied. Overall patient satisfaction with the band and recommendation of 
using the sea bands as assessed by the feedback question asking whether the patients would recommend that 
other patients wear a band when receiving chemotherapy.  
 
5.13 Procedures 
The study was approved by the Ethics Committee at the Faculty of Higher Education at An-Najah National 
University and the Ministry of Health, Nablus, Palestine. Informed consent obtained from each subject. The 
study was double blind and the patients are randomised after accepting entry into the study. One group receives 
active treatment (n=42), one placebo treatment (n=42) and one group was used as a control (n=42). 
A nurse who was not involved in caring for the patient postoperatively positioned the Seabands 
(SeaBand®, UK Ltd., Leicestershire, England) on both wrists at either the P6 point or on a non-acupoint just 
before the start of the chemotherapy. The wrists are wrapped for blinding. The patients were asked to wear the 
bands continuously for 24 hr. If the bands caused discomfort, they could be removed for 30 min every two hours. 
All patients received a 5-HT3 antiemetic (granisetron 3mg) and Dexamethazone 4 mg on the day of treatment 
before administration of chemotherapy. Antiemetic medications taken during treatment days 2–5 were not 
regulated but were recorded in a patient diary.  
Nausea and emesis were measured by a patient report diary, based on one developed by Burish (1987) 
that would be completed by patients over a five-day period. Each day is divided into four segments (morning, 
afternoon, evening, night) in each of which patients would report the severity of nausea and number of vomiting 
episodes for each period on the day of treatment and on the four following days. Severity of nausea was assessed 
on a 7-point rating scale, anchored at one end by 0 = “Not at all nauseated” and at the other end by 
7 = “Extremely nauseated.” (Morrow 1984, 1992). The patients were asked to assess their degree of nausea after 
administration of chemotherapy. Metoclopramide 10 mg is administered I.V. at the patient’s request.  
Research coordinator at the study site trained patients in the proper use and placement of the wristband. 
The P6 (Nei-Guan) was located on the pericardial meridian. P6 was located three fingers breadth (approximately 
5 cm) proximal to the proximal flexor palmar crease, about 1 cm deep, between the tendons of flexor carpi 
radialis and palmaris longus. The Sea-Band® (Sea-Band UK Ltd., Leicestershire, England, UK) was used to 
stimulate P6. It carried a plastic pearl that applied pressure on P6. Both forearms were used. A point on the 
dorsal side of both forearms, four fingers breadth proximal to the proximal flexor palmar crease was used for 
placebo stimulation. These points were marked in the same way as for P6 acupressure. The Sea-Band® was used 
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for stimulation. The control group followed the same protocol as the P6 acupressure and the non-acupressure 
groups, but had no wristband and thus was not blinded. The Sea-Bands were covered with a dressing during the 
trial period. Neither the observer nor the subjects knew if P6 or placebo stimulation was given.  
Participants were later given two questionnaires to complete at home, with instructions to return them 
back at the next chemotherapy treatment in the pre-addressed envelopes that were provided. Reminder phone 
calls were made to patients, if necessary.  Following this, the patients in the P-6 acupressure group and placebo 
group carried a set of acupressure wristbands and were instructed to wear them bilaterally throughout the 
following 5 days taking them off only when they were having a shower or a bath. Separate analyses were 
planned to examine the efficacy of the wrist band(s) in controlling acute nausea (occurring on the day of 
treatment) and delayed nausea (occurring during Days 2–5) because these were clinically relevant distinctions in 
the treatment of chemotherapy-related nausea.  
All patients completed the day-log every evening after the chemotherapy administration and for five 
consecutive evenings. Completed questionnaires were returned directly to the researchers when coming for their 
second cycle. Socio-demographic and clinical data were collected from the patients’ medical notes. 
 
5.14 Statistics and Data Analysis 
Based on the effect size observed in past studies, 42 patients are required to achieve a power of 80% at an alpha 
value set at 0.05 (Cohen 1992). 
Five outcomes related to wrist band efficacy are examined using t-tests or chi-square as appropriate. 
They are: 1) any vomiting, 2) peak severity of nausea on the day of treatment (acute nausea), 3) peak severity of 
nausea during treatment Days 2–4, (delayed nausea), 4) (QOL, and 5) amount of antiemetic medication taken at 
home. Data was coded and entered into SPSS for statistical analysis. Descriptive statistics calculated with all 
socio-demographic and clinical data. 
The primary outcome variable for this study was the severity of nausea averaged across days 2–5 of 
treatment, that is, delayed nausea. Analysis of variance (ANOVA), with a significance level of 0.05, was used to 
compare the average nausea severity between the three treatment arms. We intended to compare the sham 
location group to the correct location group if the previous analysis is significant. Secondary study outcomes 
were the severity of nausea during the first 24 hours following chemotherapy (acute nausea) and the occurrence 
of vomiting during the same 24-hour period. Data for acute nausea was analyzed in the same way as delayed 
nausea. Exploratory analyses are planned with QOL and antiemetic medication used as the outcome variables.  
 
5.15 Ethical Considerations 
The study presented in this thesis is performed in accordance with the Declaration of Helsinki and was approved 
by the Research Ethics Committee of the Faculty of Higher Education, An-Najah National University, and 
Ministry of Health Nablus, Palestine. 
To randomise the treatment is an ethical dilemma as the patient was not allowed to decide over her 
treatment. Nevertheless, all patients were given both verbal and written information before considering 
participation in the study. It was made clear that participation was voluntary, could be terminated at any time and 
that confidentiality was guaranteed. For that reason, the ethical dilemma was deemed to be small. When 
predicting risk for vomiting for the patients in the control group there were some with more than 60% risk of 
NV, yet they do not receive any form of acupressure. 
However, all patients were given allopathic prophylactic anti emetic and all the patients received anti 
emetics when required regardless of which group the patients were randomised to. That was why the ethical 
dilemma was deemed to be small.  
The patients´ integrity may be threatened when performing continuous data collection.  The results were 
presented in a way that ensured that it was not possible to identify any of the individuals. The study protocol 
concentrates on the patients’ health and well-being. It is important to know the incidence, intensity so that the 
right symptom can be addressed.  
Knowing which pharmacological and non-pharmacological preventive treatments for NV are beneficial 
and which are not will enable us to decrease the suffering for patients and the cost for society. The above made 
the ethical dilemma small in comparison with the expected benefits for the patients. To burden the patient with 
questions concerning nausea and vomiting takes time and strength. However, patients feel that they receive more 
attention and this could be regarded as positive. Furthermore, evaluation of nausea and vomiting as seen from the 
patients´ perspective, could lead to improvement in chemotherapy induced nausea and vomiting care for other 
patients in the future. 
 
6. Results  
One hundred and twenty sex patients were included in the primary data analysis. 
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6.1Demographic data (Table1) and risk factors for nausea and vomiting were shown in (table 2). 
Table (1): Demographic characteristics of patients in treatment groups. 
 Acupressure 
n=42 
Placebo 
n=42 
Control  
n=42 
Age (ys)  M(SD) 51(13) 53(12) 54(13) 
Marital status    
Unmarried n (%) 4(10) 6(14) 5(12)                             
Married 29(69) 27(64) 27(64) 
Widow 8(19) 7(17) 10(24) 
Divorced 1(2) 2(5) 0 
Children (n %)    
Yes 33(79) 30(71) 32(76) 
No 9(21) 12(29) 10(24) 
No. of children n (%)    
1-6 31(74) 31(74) 24(57) 
7-12 11(26) 11(26) 18(43) 
Accommodation (%)    
Alone 5(12) 4(10) 7(17) 
With spouse  26(62) 22(52) 24(57) 
With original family 8(19) 13(31) 8(19) 
Others 3(7) 3(7) 3(7) 
Education    
Primary 20(47) 18(43) 19(45) 
Secondary 12(28) 8(19) 9(22) 
Bachelor 4(9) 4 (10) 5(12) 
Higher education 6(14) 10(24) 3(7) 
Another 1(2) 2(4) 6(14) 
Occupation    
Full time 2(5) 4(10) 3(7) 
Partial time 3(7) 3(7) 2(5) 
House wife 36(85) 34(81) 37(88) 
Student  1(2) 1(2) 0(0) 
The three groups were similar with respect to demographic characteristics, no statistically significant 
difference were seen between the groups, homogeneity of a group subjects has implicated for study design. 
(Table 1). 
Table (2): Risk factors for nausea and vomiting in the acupressure, placebo and control groups. 
Variable 
Acupressure 
(n=42) 
Placebo 
(n=42) 
Control 
(n=42) 
Health  
Chronic illness 
No chronic illness 
 
33.3% 
66% 
 
28.6% 
71.4% 
 
28.6 
71.4% 
Nausea in pregnancy 40.5% 33.3% 57.1% 
Vomiting in pregnancy 40.5 33.3% 42.9% 
Nausea in menstruation 21.4% 33.3% 9.5% 
Menstruation vomiting 7.1% 2.4% 7.1% 
Motion sickness 21.4% 28.6% 31.0% 
Motion vomiting 21.4% 14.3% 21.4% 
Smoking 2.4% 0 0 
The above table clarifies percentage of risk factors for the participant among the three groups, no 
differences among the three groups in relation to the above risk factors. 
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6.2 Acute nausea and vomiting/retching: 
Table (3): Incidence & severity of nausea, vomiting/retching of patients in the treatment groups during first 24 h 
following chemotherapy. 
Day one, during the 
first 24 h following 
chemotherapy 
Acupressure 
(n=42) 
Placebo 
(n=42) 
Control 
(n=42) 
P value 
13acupressure 
compared to  
control 
P-value 
acupressure 
compared to 
placebo 
Incidence of 
Vomiting & 
Retching n (%) 
 
28 (67) 
 
 
32 (76) 
 
 
30 (71) 
 
 
p= 0.6369 
 
p= 0.3340 
The mean number 
of acute emetic 
episodes 
2.23 (1.25) 2.5 
(1.81) 
 
2.25 (1.94)  
p= 0.9050 
 
p= 0.1107 
Incidence of acute 
nausea 
 n (%) 
a dichotomous 
fashion (yes/no) 
26 (62) 
 
30 (71) 
 
30 (71) 
 
 
p= 0.3545 
 p= 0.3545 
Accumulative 
incidence of nausea 
≥3(0-6 scale) in the 
first 24hs of 
chemotherapy 
 
 
18(43) 
 
 
28(67) 
 
 
24(57) 
 
 
P= 0.01904 P= 0.0284 
Nausea severity (0-
6 scale) in first 24 
hours after 
chemotherapy 
Mean (SD) 
 
1.62 
 (2.04) 
 
 
2.17 (2.09) 
 
1.64 (1.99) 
 
p= 0.8967 
p= 0.0006 
No significant differences were found in the incidence of acute nausea or emesis 24- h following 
chemotherapy by treatment groups. Significant difference was found in the severity of early nausea (0-6 scale) in 
the acupressure group M (SD) 1.62 (2.04) as compared to placebo group 2.17 (2.09), p=0.0006. (Table3). The 
incidence of moderate to extreme nausea ≥ 3 (0-6 scale) for the first 24hs of chemotherapy was significantly less 
in acupressure group18 (43) compared to both placebo 28 (67) P = 0.0284 and a control 24 (57) P = 0.01904. No 
significant differences in the incidence of acute vomiting & retching were found by treatment group 67%  
(28/42) in acupressure group and 76% (32/42) in the placebo group (p= 0.6369) (p=0.3340) compared to control 
group  71%  (30/42) respectively. There is no significant difference of the mean number of acute emetic episode 
was seen between the groups. The mean (SD) number of acute emetic episodes in acupressure group 2.23 (1.25), 
p= 0.9050, placebo 2.50 (1.81) p=0.1107 compared to control 2.25 (1.94) respectively (Table 3),   
5.3 Delayed vomiting: The results are accumulating covering the entire period. 
Table (4): Incidence of delayed vomiting episodes: Days 2-5, n (%) in the three groups after chemotherapy 
Incidence of 
vomiting  
days 2-5 
 
Acupressure 
(n=42) 
n(%) 
Placebo 
(n=42) 
n(%) 
Control 
(n=42) 
n(%) 
p-value 
acupressure 
compared to 
control 
p-value 
acupressure 
compared to 
placebo 
p-value 
placebo 
compared 
to control 
Day 2 17 (40) 20 (48) 14 (33) P=0.4976 P=0.5097 P=0.1823 
Day 3 17 (40) 25 (60) 18 (43) P=0.8248 P=.0809 P=0.1265 
Day 4 9 (21) 14 (33) 12 (29) P=0.4497 P=0.2212 P=0.6369 
Day5 6 (14) 7 (17) 10 (24) P=0.2664 P=0.7629 P=0.4152 
The whole 
period 
20 (48) 27 (64) 24 (57) 
p= 0.3822 
p= 0.1239 p= 0.5027 
The whole period incidence of delayed vomiting episodes days 2-5 was 48% (20/42), 64% (27/42), and 
57% (24/42) in the acupressure, placebo and control group respectively. No significant differences were found 
between the groups. (Table 4). 
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6.4 Delayed nausea: The results are accumulating covering the entire period:. 
Table (5): Mean (SD) of delayed nausea severity (0-6) scale. Patients who scored their nausea >0. Comparison 
between the three groups for the days 2-5 after chemotherapy.  
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Day 2 
Morning 
12:00 
18:00 
Before sleep 
Total Mean 
(SD) 
 
1.43 (2.01) 
1.85 (2.05) 
1.80 (2.14) 
1.87 (2.06) 
1.73 (1.56)* 
 
1.57(1.83) 
1.57 (1.87) 
1.40 (1.72) 
1.52 (1.82) 
1.51 (1.87) † 
 
2.33 (2.02) 
2.09 (1.97) 
2.30 (1.89) 
1.88 (1.90) 
2.75 (1.94)* † p= 
0.0000 
p= 
0.1526 p= 0.0000 
Day 3 
Morning 
12:00 
18:00 
Before sleep 
Total Mean 
(SD) 
 
1.56 /1.98) 
1.87 (2.09) 
1.68 (2.04) 
1.87 (2.19) 
1.74 (2.07) *** 
 
1.59 (1.87) 
1.40 (1.87) 
1.40 (1.83) 
1.21 (1.81) 
1.39(1.84)*  
 
2.30 (2.10) 
2.38 (2.08)  
2.09 (2.05) 
2.02 (2.07) 
2.19(2.07) *† 
p= 
0.0000 
p= 
0.0214 p= 0.0000 
Day 4 
Morning 
12:00 
18:00 
Before sleep 
Total Mean 
(SD) 
 
1.51 (1.81) 
1.39 (1.74) 
1.31 (1,66) 
1.31 (1.73) 
1.37 (1.73)* 
 
1.54 (1.84) 
1,23 (1.73) 
1.16 (1.72) 
1.07 (1.62) 
1.25 (1.72) † 
 
1.88 (1.96) 
2.04 (2.07) 
1.78 (1.84) 
1.52 (1.77) 
1.80(1.91)* † 
 
p= 
0.0049 
 
p= 
0.4017 
 
p= 0.0003 
Day 5 
Morning 
12:00 
18:00 
Before sleep 
Total Mean (SD 
 
1.07 (1.61) 
0.97 (1.47) 
0.97 (1.58) 
0.97 (1.65) 
0.99 (1.57)* 
 
1.33 (1.83) 
1.19 (1.81) 
1.09 (1.69) 
1.14 (1.63) 
1.18 (1.74) 
 
1.61 (1.80) 
1.40 (1.75) 
1.33 (1.81) 
1.23 (1.58) 
1.39 (1.73)* 
 
p= 
0.0000 
 
p= 
0.1541 p= 0.1395 
The whole 
period (2-5 
days) 
Total mean (SD 
 
1.45 (1.73)* 
 
1.33(1.66) † 
 
2.03 (1.91)* † 
p= 
0.0002 
p= 
0.4116 p= 0.0010 
*P < 0.05 when P6 acupressure is compared to control group. 
**P< 0.05 when P6 acupressure is compared to placebo group. 
† P< 0.05 when placebo is compared to control group. 
Further analyses indicated that significant difference existed in the intensity of delayed nausea by 
acupressure group, mean (SD) 1.45 (1.73), p= 0.0002 as compared to control 2.03 (1.91)  for the whole period. 
Significant difference also existed in the intensity of delayed nausea by placebo group mean (SD) 1.33 (1.66), 
p=0.0010 as compared to control 2.03 (1.91), here we noted a placebo effect (Table 5). 
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Table (6):  Incidence of delayed nausea Days 2-5 in the three groups. Values given as n (%) 
Incidence of delayed 
nausea day 2-5 
Patients who answers 
yes 
Acupressure 
(n=42) 
n(%) 
Placebo 
(n=42) 
n(%) 
Control 
(n=42) 
n(%) 
P-value 
Acupressure vs 
control 
P-value 
Placebo 
vs 
control 
Day 2 25 (60) 24(57) 32 (76) p= 0.1020 p= 0.0641 
Day 3 24(57) 21(50) † 32(76) † p= 0.0641 p= 0.0129 
Day 4 22(52)* 22(52) † 31(74)* † p= 0.0419 p= 0.0419 
Day 5 17 (40)* 18(43) 26 (62)* p= 0.0495 p= 0.0805 
The whole period 17 (40)* 18 (43) 26(62)* p= 0.0495 p= 0.0805 
*P < 0.05 when P6 acupressure is compared to control group.  
† P< 0.05 when placebo is compared to control group.  
The acupressure group had a statistically significant reduction in the incidence of delayed  nausea 40% 
(17/42) as compared to the control group 62% (26/42) (p= 0.0495) ((Table 6).  
Table (7):  Accumulative incidence of delayed nausea Days 2-5 ≥ 3 (0-6 scale) of moderate to very severe nature 
in the three groups. Values given as n(%) 
Delayed nausea 
Day 2-5 
≥3 (0-6 scale) 
Acupressure 
n=42 
n(%) 
Placebo 
n=42 
n(%) 
Control 
n=42 
n(%) 
P-value 
Acupressure vs  
control 
P-value 
Placebo 
vs 
control 
Day 2 18 (43)* 18 (43) † 28 (67)* † p= 0.0284 p= 0.0284 
Day 3 17 (40) 16 )38) 22 (52) p= 0.2740 p= 0.1884 
Day 4 14 (33)* 13 (31)† 23 (55)* † p= 0.0479 p= 0.0275 
Day5 7 (17)* 12 (29) 18 (43)* p= 0.0087 p= 0.1719 
The whole period 
days 2-5 
23 (55)* 22 (52) † 33 (79)*† 
 
p= 0.0206 
 
p= 0.0116 
 *P < 0.05 when P6 acupressure is compared to control group. 
 **P< 0.05 when P6 acupressure is compared to placebo group.  
† P< 0.05 when placebo is compared to control group.  
The percentage of the patients who had delayed moderate to very severe nausea day 2-5 (≥ 3 on 0-6 
scale) in the acupressure group is 55% (23/42) (p= 0.0206), in the placebo group 52% (22/42) (p= 0.0116), a 
statistically significant reduction existed as compared to control 79% (33/42),  here we noted as a placebo effect 
(Table 7) 
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6.5 Delayed emetic episodes: The results are accumulating covering the entire period: 
Table (8):  Number of delayed emetic episodes Days 2-5 in the three groups. Values given as Mean (SD) 
Mean (SD) of No. 
emetic episodes 
The patients who 
vomited only  are 
included 
Acupressure 
(n=42) 
Mean (SD) 
Placebo 
(n=42) 
Mean (SD) 
Control 
(n=42) 
Mean (SD) p
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Day 2 
Morning 
12:00 
18:00 
Before sleep 
Total 
 
1.5 (0.83) 
1.5 (0.83) 
2 (0.98) 
1.8 (0.91) 
1.7 (0.88) 
 
1.78 (1.11) 
2.1 (1.44) 
2 (1.32) 
2 (1.16) 
1.97( 1.25) 
 
2.45 (1.5) 
2.57 (1.38) 
2.27 (1.34) 
2.3 (1.10) 
2.39 (1.33) 
P= 
0.0000 
P= 
0.0907 
P= 
0.0117 
Day 3 
Morning 
12:00 
18:00 
Before sleep 
The whole period 
 
1.75 (0.92) 
1.75 (0.99) 
2.22 (1.18) 
2.4 (1.30) 
2.03 (1.09) 
 
1.46 (0.839 
1.83 (1.05) 
1.46 (0.86) 
1.71 (0.81) 
1.61 ( 0.88) 
 
2.38 (1.54) 
2.33 (1.37) 
3,00 (1.53) 
2.28 (1.15) 
2.49 (1.39) 
p= 
0.0035 
p= 
0.0058 
p= 
0.0000 
Day 4  
Morning 
12:00  
18:00 
Before sleep 
The whole period 
 
1.12(0.51) 
1.40 (0.56) 
1.8 (0.73) 
1.66 (0.83) 
1.49 (0.65) 
 
1.66 (0.76) 
1.33 (0.52) 
1.37 (0.61) 
1.6 (0.76) 
1.49 (0.66) 
 
2 (1.21) 
2.33 (1.24) 
2.33 (1.19) 
2.66 (1.20) 
2.33 (1.21) 
p= 
0.0000 
p= 
1.0000 
p= 
0.0000 
Day 5 
Morning 
12:00 
18:00 
Before sleep 
The whole period 
 
1.25 (0.43) 
1.66 (0.79) 
1.5 (0.57) 
0.21 (0.57) 
1.5 (0.64) 
 
1.66 (0.85) 
1.66 (0.45) 
1.00 (0.51) 
1.00 (0.51) 
1.33 (0.58) 
 
1.8 (1.08) 
2.33 (1.12 
2.04 (2.33) 
2.2 (1.01) 
2.09 (1.13) 
p= 
0.0001 
p= 
0.2327 
p= 
0.0000 
The whole period 2-5 
day 
1.68 (0.86)* 1.6 (0.82)† 2.07(1.20)*† p= 
0.0109 
p= 
0.5900 
p= 
0.0020 
*P < 0.05 when P6 acupressure is compared to control group.  
† P< 0.05 when placebo is compared to control group.  
The mean number of delayed emetic episodes days 2-5 was significantly less in the acupressure group 
mean (SD) 1.68 (0.86) as compared to control 2.07(1.20) p=0.0109  and less in the placebo group 1.6 (0.82) as 
compared to control P= 0.0020 (Table 8).  
 
6.6 Requirement of rescue antiemetic: 
Table (4.9): Requirement of rescue antiemetic in the three group’s days 1-5 
The whole 
period 
Acupressure 
(n=42) 
Placebo 
(n=42) 
Control 
(n=42) 
P- value 
Acupressure 
vs control 
p-value placebo 
vs  
control 
`Not required 
antiemetic 
19 16 10 p=0.0389 
 
p= 0.1568 
 
Required 
antiemetic 
23 (55)* 26 (62) 32 (76)* 
p= 0.0389 
p= 0.1568 
 
*P < 0.05 when P6 acupressure is compared to control group.  
Requirement of rescue antiemetic was significantly lower in P6-acupressure (55%, 23/42), as compared to 
control group (76%, 32/42) (p= 0.0389) (Table 9). 
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6.7 Analyses of QOL by using FACT-G. The results are accumulating covering the entire period: 
Table (10): Comparison of the study outcomes by Analyses of QOL by using FACT-G  
FACT-G (version 4) Acupressure 
(n=42) 
Placebo 
(n=42) 
Control 
(n=42) 
P value 
Acupressure vs  
control 
Physical well-being 
(PWB) 
16 15 15  
Social/family wellbeing 
SWB) 
24 20 19  
Emotional well-being 
EWB) 
16 15 17  
Functional well- being 
(FWB) 
18 17 18  
Over all QOL score 108 point 74 67 69 p= 0.4720 
Exploratory analyses of QOL by using FACT-G was shown that no statistically significant differences 
between groups were observed for the overall items response rate of the FACT-Scale which were 74/108, 
67/108, 69/108 in the acupressure, placebo and control group respectively (Table 10). The FACT-Scale is 
considered to be an acceptable indicator of patient QOL as long as overall item response rate is greater than 
80%. 
 
6.8 Overall patient satisfaction and recommendations for other patients to wear acupressure bands 
Table (11):  Overall patients´ satisfaction with acupressure and if they would recommend other patients to wear 
bands when receiving chemotherapy.  
 Acupressure 
(n=42) 
Placebo 
(n=42) 
P-value 
0.05 
Satisfaction with P-6 acupressure ≥ 3 (0-6 scale) n 
(%) 
 
35 (81)* 
 
27(64)* 
 
p= 0.0471 
Recommendation P-6 acupressure ≥ 3 (0-6 scale)  
34 (79)* 
 
26 (62)* 
p= 0.0533 
*P < 0.05 when P6 acupressure is compared to control group.  
The patients were satisfied with the antiemetic treatment in (P6-acupressure, and placebo-acupressure). 
The percentage of the patients (≥ 3 on 0-6 scale) who were satisfied with treatment was 81% (35/42) in the P6-
acupressure group, and 64% (27/42) in the placebo group (p= 0.0471). Percentage of the patients who would 
recommend acupressure treatment was 79% (34/42)  in the P6-acupressure group, and 62% (26/42) in the 
placebo group (p= 0.0533). (Table 11). 
 
7. Discussion 
Findings from the present study confirmed that acupressure is efficacious for control of delayed chemotherapy 
related nausea and emesis and is a value-added method in addition to pharmaceutical management for women 
undergoing treatment for breast cancer. This is in accordance with the accumulating body of evidence related to 
acupressure during chemotherapy and shows that acupressure is a safe and complementary option in the 
management of chemotherapy-related nausea and vomiting (Roscoe et al., 2005; Shin et al., 2004; Dibble, 
2000). 
Our study is consistent with the study results of Dibble et al (2000) which were shown that finger 
acupressure may decrease nausea among women undergoing chemotherapy for breast cancer. Our study is also 
in agreement with the study of Roscoe et al (2006) who showed that acupressure wrist bands were efficacious 
and may be appropriate form of adjuvant therapy for nausea management for breast cancer patients, especially 
those who are most at risk for experiencing severe nausea following chemotherapy treatment 
 
7.1 Acute nausea 
Significant difference was found in the severity of early nausea (0-6 scale) at the first day in the acupressure 
group M (SD) 1.62 (2.04) as compared to placebo group 2.17 (2.09), p= 0.0006 which is consistent with the 
study of Nyström et al (2008) who demonstrated that acupuncture treatment in cancer patients can be associated 
with a significantly reduced intensity of nausea during a period of chemotherapy in their final phase of life.  
The largest study of acupressure use for chemotherapy-related nausea and vomiting (n = 739) to date 
showed that the use of antiemetic pills was lower in the acupressure group (mean pills = 5.1) compared to the 
control group (mean pills = 9.7). This result is in agreement with the result of our present study regarding the 
requirement of rescue anti emetics which was significantly lower in P6-acupressure (55%, 23/42), compared to 
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control group (76%, 32/42) (p= 0.0389). However, there were some key differences between this study and our 
study in that some patients in the latter study received cisplatin based chemotherapy, which is considerably more 
emetogenic and difficult to manage than the types of chemotherapy used in the present study. Also, the Roscoe 
et al. Study (Roscoe, 2003) used patients with different cancer diagnoses, hence it was not as homogeneous as 
our study. It also seemed that their patients used mainly dexamethasone/other corticosteroids for the 
management of delayed nausea and vomiting whereas all of our patients received dexamethasone once. It is well 
known that dexamethasone is highly effective in managing delayed nausea and vomiting, although many 
clinicians, are sceptical of the use of steroids for prolonged periods of time. Hence, the use of dexamethasone 
may have contributed to the better control of nausea and vomiting in the study by (Roscoe et al., 2003), 
minimising the possible effect of wrist Bands. Such use of dexamethasone is a key factor to consider in future 
antiemetic trials of this kind.  
In our study, no significant differences were found in the incidence of acute nausea or emesis 24- h 
following chemotherapy by treatment groups. This is inconsistent with the pooled results of 11 randomized 
controlled trials evaluating acupuncture-point stimulation plus antiemetic for chemotherapy-induced nausea and 
vomiting showed a significant reduction in the proportion of patients experiencing acute vomiting (Esso et al., 
2005). On the other hand, in the current study acupressure seems to reduce chemotherapy-induced acute nausea 
severity A significant difference was found in the severity of early nausea (0-6 scale) in the acupressure group M 
(SD) 1.62 (2.04) as compared to placebo group 2.17 (2.09), p= 0.0006, this is consistent partially with the study 
of Ezzo et al (2005) who showed a marginal statistical significance for reducing severity of acute nausea. 
Although other studies have also shown positive (and negative) effects with the use of acupressure in 
managing chemotherapy-induced nausea and vomiting, they are not easily comparable with the current study, as 
the method of acupressure differed. Past studies have used either finger acupressure and use of more than the P6 
point (Dundee et al., 1991), or use of the Relief band / transcutenuous electrical nerve stimulation at the P6 point 
(Pearl, 1999, Treish et al., 2003; Roscoe et al., 2005).  Mixed chemotherapy protocols and antiemetics used also 
make comparisons difficult. Furthermore, in another study by Roscoe et al (2005), where gender and type of 
chemotherapy were controlled, the placebo control group used  an  active Wrist Band, which may have led to the 
negative findings reported. It may be that constant  pressure on the P6 point (as in the acupressure Wrist Bands) 
may produce better results than pressing the stud only or using electrical nerve stimulation to the point (as in the 
Relief Band). 
 
7.2 Acute vomiting  
In the current study, no significant differences were found in the incidence of acute emesis 24- h following 
chemotherapy by treatment groups. This finding is consistent with Dundee and Yang (1990) found that 
acupressure, by itself, was not sufficient to  prevent vomiting in chemotherapy patients. Our results also are in 
agreement of Roscoe et al, (2005) who did not show that acupressure bands were efficacious when used as an 
adjunct  to pharmacological anti emetics for the control of the incidence of chemotherapy-related vomiting  in 
female breast cancer patients.  
 
7.3 Delay nausea 
Incidence of delayed nausea was significantly different among groups, with 55% of  the acupressure group, 52% 
of the placebo group, and 79% of the control group p<0.05). Both the true acupressure and placebo acupressure 
groups were significantly different from the control group. Our results are consistent with study results of 
Ferrara-Love et al., (1996).  
Patients randomized to the acupressure group had significantly less delayed nausea on (Days 2–5) of 
treatment than patients in the control. This reduction in nausea, however, did not extend to the acute phase 
following treatment (Day 1), nor was there a reduction in emesis. It cannot be ascertained from our data why the 
bands were helpful on (Days 2–5) of treatment  but not on the first day. It may be related to the fact that the acute 
and delayed treatment-related nausea have different etiologist. So our results were not consistent with the study 
of (Roscoe et al., 2003). 
Our results are consistent with the results of Pearl and colleagues (1999) who examined the efficacy of 
acu-stimulation in 42 patients in a randomized, double-blind, placebo- controlled crossover trial, with a follow-
up. For the 18 patients who completed the crossover component of the study, patients in the active band cycle, as 
compared to the placebo band cycle, reported a significantly lower severity of nausea during the second through 
fourth post-treatment days (O`Brien et al., 1996). Our results are consistent with the results of study there 
acupuncture combined with antiemetic which can effectively decrease the incidence and degree of cisplatin-
induced delayed nausea and vomiting (Sima & Wang, 2009) 
 
7.4 Delayed emesis 
Our results regarding the mean number of delayed emetic episodes days 2-5 was significantly less in the 
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acupressure group  M (SD) 1.68 (0.86) as compared to control 2.07(1.20,) p=0.0022  and less in the placebo 
group 1.6 (0.82 as compared to control, 2.07(1.20) P= 0.0005. This result is consistent with the study of Shen et 
al, (2000) which showed that the number of emesis episodes occurring during the 5 days was lower for patients 
receiving electro acupuncture compared with those receiving minimal needling or pharmacotherapy alone?  
Patients in acupressure & placebo groups reported substantially lower rates of delayed nausea compared 
to patients in the control group, thereby indicating the presence of a powerful placebo effect. This is in consistent 
of a study (Alkaissi,1999)  of PONV which had  a similarly-designed 3-arm acupressure band study of 60 
patients undergoing minor outpatient gynaecological surgery also it was reported positive results for placebo 
bands (Alkaissi,1999). Patients randomized to both the active acupressure band condition and to the placebo 
band condition had significantly less postoperative nausea than patients randomized to the no band control group 
(P= 0.05). There were no differences in the amount of nausea reported between the two acupressure band groups 
(Alkaissi, 1999). 
In the current study no significant differences were found between the groups in the incidence of 
delayed vomiting episodes days 2-5, this was consistent with other studies in which no significant differences 
were found between the groups and delayed symptoms remain a problem for many cancer patients (Dibble 2003, 
2004, Roscoe et al., 2005) 
 
7.5 Quality of life  
Nausea has obvious consequences on the quality of life, and it is not unusual for patients to experience nausea as 
a greater problem than pain (Strang et al., 1999). Therefore expert  panels (Gralla et al., 1999; Hesketh et al., 
1998) emphasize the need for additional ways to reduce symptoms. Chemotherapy induced nausea and vomiting 
can impair a patient’s quality of life (Osoba, 1997), cause emotional distress, (Love et al., 1989) and aggravate 
cancer-related symptoms 
In our study, no statistically significant differences between groups were observed for the overall items 
response rate of the FACT-Scale which were 74/108, 67/108, 69/108 in the acupressure, placebo and control 
group respectively which is inconsistent with the other study which showed that psychological well-being 
improved in women with breast cancer randomized to treatment with either applied relaxation and electro-
acupuncture. On the other hand, our study is in complete agreement with the findings of Roscoe et al (2005). 
 
8. Conclusion 
We conclude that acupressure showed benefit for delayed nausea and the mean number of delayed emetic 
episodes, but not for the incidence of delayed vomiting, early vomiting or  for acute nausea  
Acupressure, therefore, may offer an inexpensive, convenient, self- administered intervention for 
patient on chemotherapy to reduce nausea and vomiting at home on days 2-5 of chemotherapy. 
It is not clear why acupressure was effective for delayed nausea and not the incidence of delayed 
vomiting, but some trials for other kinds of nausea and vomiting have produced the sham outcome.  It may be 
that, to influence vomiting, stronger form of P6 stimulation is needed. Acute nausea remains a problem even 
with the use of current antiemetic. It is not known why acute symptoms are so difficult to treat with conventional 
medications, but it is apparent that acupressure affects little for acute nausea induced by chemotherapy treatment 
of cancer patient. 
 
9. Recommendation 
P6- Acupressure is well-tolerated and effective as an adjunct in reducing chemotherapy-related nausea. Based on 
our results, we conclude that P6-acupressure, as an addition to standard, modern antiemetic therapy, has reduced 
delayed emesis in female patients undergoing doxorubicin- based chemotherapy. It is an alternative means of 
therapy aside from conventional or expensive antiemetic drugs and this is worthy of further investigation. The 
results of this study concur with that of other randomized controlled trials which showed that acupuncture-point 
stimulation reduced the proportion of patients experience in chemotherapy-induced vomiting.  
Acupressure is easily learnt and taught and patients should be informed about  its potential role and 
taught how to apply it. Leaflets about acupressure for the management of nausea and vomiting could be available 
in chemotherapy units so that patients who are interested to use such a technique are encouraged to come 
forward and learn more from nurses or other health professionals. This can add to the patients’ options of their 
antiemetic approaches and empower them to be involved in the management of these distressing side effects.. 
 
10. Implications for Oncology Nurses 
Studies about acupressure have concluded that acupressure is an important adjunct to pharmaceuticals in 
managing CINV (Dibble et al., 2000; Shin et al., 2004). Those studies as well as the current study suggest that 
oncology clinicians can include acupressure in their list of options for the management of CINV, especially 
delayed nausea and vomiting. Specific recommendations provided by oncology nurses are not only useful but 
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also are very appreciated by patients. 
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